These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 22059152)

  • 21. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
    Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
    Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
    Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
    Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
    Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
    Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
    Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways.
    Pattanayak SP; Bose P; Sunita P; Siddique MUM; Lapenna A
    Biomed Pharmacother; 2018 Dec; 108():297-308. PubMed ID: 30227322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation.
    Sorrentino V; Nelson JK; Maspero E; Marques ARA; Scheer L; Polo S; Zelcer N
    J Lipid Res; 2013 Aug; 54(8):2174-2184. PubMed ID: 23733886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AMP-activated protein kinase suppresses LXR-dependent sterol regulatory element-binding protein-1c transcription in rat hepatoma McA-RH7777 cells.
    Yang J; Craddock L; Hong S; Liu ZM
    J Cell Biochem; 2009 Feb; 106(3):414-26. PubMed ID: 19125418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
    Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
    Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
    Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
    Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
    Aguila B; Morris AB; Spina R; Bar E; Schraner J; Vinkler R; Sohn JW; Welford SM
    Cancer Lett; 2019 Oct; 462():33-42. PubMed ID: 31377205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
    Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
    J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting SREBP-1-driven lipid metabolism to treat cancer.
    Guo D; Bell EH; Mischel P; Chakravarti A
    Curr Pharm Des; 2014; 20(15):2619-26. PubMed ID: 23859617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
    Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
    J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FHL2 interacts with EGFR to promote glioblastoma growth.
    Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
    Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.